Italy's PharmaNutra H1 revenue rises on foreign markets, new business units strength
Italy's PharmaNutra H1 revenue rises on foreign markets, new business units strength
Overview
Italy mineral supplement maker's H1 2026 revenue rose 17.9% yr/yr
EBITDA for H1 2026 grew 6.2% yr/yr, net profit up 8.1%
Growth driven by international markets and flagship products, new units grew 102% yr/yr
Outlook
Company expects new business units to drive further growth and profitability
PharmaNutra sees international markets as key growth drivers for future development
Result Drivers
INTERNATIONAL EXPANSION - Revenue from foreign markets rose 34.8% yr/yr, accounting for 38.6% of total revenue
NEW BUSINESS UNITS - New business units contributed about EUR 5 mln to total revenue, up 102% yr/yr
FLAGSHIP PRODUCT GROWTH - SiderAL line sales grew 19.6%, with additional strong growth from Cetilar (+18.3%), Apportal (+12.9%) and Sidevit B12 (+67.6%)
Company press release: ID:nBIA5fh3Ln
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
H1 Revenue |
| EUR 73 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for PharmaNutra S.p.A. is €93.00, about 17.6% above its September 10 closing price of €79.10
The stock recently traded at 28 times the next 12-month earnings vs. a P/E of 32 three months ago
Reuters Recommended Reads
Sept 10 - Italy's Orsero H1 revenue rises on high value fruit
Sept 9 - EssilorLuxottica board backs CEO Milleri after criticism from Del Vecchio heir
Sept 9 - Italian banks' lending to firms accelerates in July
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)